These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical evaluation of the carbomedics prosthesis: experience at providence health system in Portland.
    Author: Minakata K, Wu Y, Zerr KJ, Grunkemeier GL, Handy JR, Ahmad A, Starr A, Furnary AP.
    Journal: J Heart Valve Dis; 2002 Nov; 11(6):844-50. PubMed ID: 12479287.
    Abstract:
    BACKGROUND AND AIMS OF THE STUDY: This study details the authors' experience with the CarboMedics bileaflet mechanical prosthesis, and assesses the valve's efficacy in terms of early mortality and long-term morbidity. METHODS: Between July 1994 and December 2000, a total of 696 CarboMedics valves was implanted in 616 patients. Aortic valve replacement (AVR) was performed in 350 (57%) patients, mitral valve replacement (MVR) in 161 (26%), double (aortic + mitral) valve replacement (DVR) in 79 (13%), and other procedures in 26 (4%). RESULTS: There were 32 operative deaths. Operative mortality was 4.3% for AVR, 6.8% for MVR, and 7.6% for DVR. Linearized rates for late death were 3.4%/patient-year (pt-yr), 5.5%/pt-yr and 7.7%/pt-yr for AVR, MVR and DVR, respectively. Survival at five years was 80.1% for AVR, 73.0% for MVR, and 64.6% for DVR (p = 0.004). Freedom from reoperation at five years was 97.6% for AVR, 98.1% for MVR, and 94.1% for DVR (p = 0.718); freedom from thromboembolism at five years was 96.3% for AVR, 98.6% for MVR, and 88.3% for DVR (p = 0.04). Linearized rates of late thromboembolism were 0.7%/pt-yr, 0.4%/pt-yr and 2.3%/pt-yr, respectively. Freedom from PVE at five years was 98.4% for AVR, 97.0% for MVR, and 89.7% for the DVR group (p = 0.172). Linearized rates of PVE were 0.5%/pt-yr, 0.9%/pt-yr and 1.8%/pt-yr, respectively. Freedom from anticoagulant-related bleeding at five years was 98.0% in the AVR group, 97.8% in the MVR group, and 88.3% in the DVR group (p <0.001); linearized rates of this event were 0.4%/pt-yr, 0.6%/pt-yr and 3.2%/pt-yr, respectively. One valve thrombosis was found after MVR, and another in the mitral position after DVR. CONCLUSION: Early and intermediate-term follow up of the CarboMedics prosthesis indicates that the clinical performance of this valve is satisfactory, and results are comparable with those obtained for other mechanical valves.
    [Abstract] [Full Text] [Related] [New Search]